Treating HIV and hepatitis C among people who use drugs works best when testing, treatment, and medications for opioid use disorder (MOUD) sit in the same place, offered by a team the community trusts. People who inject drugs carry elevated risk of both infections because shared injection equipment transmits them, and the same barriers that keep people out of general health care, distance, cost, and stigma, keep them from testing and treatment too. The answer is co-location: put HIV and HCV testing, treatment, and MOUD together, on a schedule people can rely on, so a single visit addresses the infection and the substance use driving the risk. For treatment leaders, health plan operators, and public health managers, that integration is the practical lever.
The stakes rise with time. Hepatitis C prevalence among people who inject drugs climbs steeply the longer a person injects, and over 2,500 new HIV infections occur each year among people who inject drugs. Reaching people early, and reaching them at all, depends on bringing services to where they are. A behavioral health satellite clinic network can co-locate testing, treatment, and MOUD in communities that have none of it within reach.
People who inject drugs face high risk of HIV and hepatitis C because both viruses spread through shared injection equipment. Sharing a syringe or other supplies passes blood, and with it the virus, from one person to the next. That transmission route is efficient, which is why infection rates in this population run far above the general public.
The risk compounds with barriers to care. Many people who inject drugs have limited access to health care, unstable housing, and experiences of stigma that make them avoid clinics. Testing that would catch an infection early does not happen, and treatment that would cure hepatitis C or control HIV does not start. The result is a population at high biological risk that is also least likely to be reached by conventional, clinic-based care. Closing that gap means changing where and how services are offered.
Hepatitis C is common among people who inject drugs, and prevalence rises sharply with the number of years a person has been injecting. Antibody prevalence climbs from 2.9% in people injecting less than a year to about 28.9% at three years, 40 to 48% at five to seven years, and 59.7% at eight or more years.
That gradient carries a clear message for program design: reach people early. A person in their first year of injecting has a much lower chance of infection than someone eight years in, so testing and prevention delivered early prevent infections that would otherwise accumulate. It also means that among people who have injected for years, a large share are already infected and need treatment, not only prevention. A program should plan for both, catching new cases early and treating the established infections that a long-injecting population brings.
Treating hepatitis C and opioid use disorder together works because the same person often has both, and addressing one without the other leaves the risk in place. Concurrent HCV and OUD treatment for people who inject drugs is feasible and effective. Curing hepatitis C while stabilizing opioid use disorder treats the infection and reduces the ongoing behavior that transmits it.
Separating the two conditions across different providers introduces the same handoff problem that stalls other kinds of integrated care. A person referred from an HCV clinic to a separate addiction program, or the reverse, often does not complete either. Treating both on one plan keeps the person engaged, and MOUD itself supports HCV treatment by stabilizing daily life enough to complete a course of medication. For a program, integration is both clinically sound and operationally simpler, because one team holds the full picture.
Syringe services open the door to testing and treatment by creating regular, trusted contact with people who otherwise avoid the health care system. Syringe services programs bridge people to HIV and HCV testing and treatment and to MOUD, and they are associated with about 50% lower HIV and HCV incidence among people who inject drugs.
The relationship is what makes the bridge work. Someone who comes in for clean supplies returns, is known, and over time accepts an offer of testing they would never seek in a clinic. A positive result then leads directly into treatment because the connection already exists. This is why syringe services are not separate from HIV and HCV care but a front door to it. Building testing and treatment onto the same contact, rather than referring people elsewhere, keeps the door open all the way through.
A mobile program co-locates testing, treatment, and MOUD by carrying all three on one unit, staffed by a dedicated team, on a predictable schedule in communities without fixed-site care. One stop can offer HIV and HCV testing, start or continue treatment, and provide MOUD, so a person addresses the infection and the substance use in a single visit rather than three separate journeys.
Making that model hold depends on staffing, planning, and payment:
Both viruses spread through shared injection equipment, so sharing syringes and supplies transmits them efficiently within this population. The risk is compounded by limited access to health care, unstable housing, and stigma that keep people from testing and treatment. Reaching people where they are, rather than waiting for them to come to a clinic, is what closes the gap.
Hepatitis C prevalence rises steeply with years of injecting. Antibody prevalence is about 2.9% in people injecting less than a year, roughly 28.9% at three years, 40 to 48% at five to seven years, and 59.7% at eight or more years. That gradient means early testing and prevention matter, and that a large share of long-injecting people are already infected and need treatment.
Yes. Concurrent treatment of hepatitis C and opioid use disorder for people who inject drugs is feasible and effective. Curing hepatitis C while stabilizing opioid use disorder treats the infection and reduces the behavior that transmits it, and MOUD supports completion of HCV treatment by stabilizing daily life. Treating both on one plan keeps people engaged better than referring them between separate programs.
Syringe services programs create regular, trusted contact with people who avoid the health care system, which opens the door to testing and treatment. They bridge people to HIV and HCV testing and treatment and to MOUD, and they are associated with about 50% lower HIV and HCV incidence among people who inject drugs. Building testing and treatment onto the same contact keeps people engaged all the way through.
If you lead a treatment program or health plan and want to reach people who inject drugs with testing, treatment, and MOUD in one place, a mobile unit can carry all three. Learn how a behavioral health satellite clinic network can co-locate HIV and HCV care with substance use treatment where people already are.